The renegotiated North American Free Trade Agreement (NAFTA) deal that Trump signed at the end of 2018 guarantees new monopoly rights for big pharmaceutical companies, so they can avoid generic competition and keep U.S. drug prices high. The revised NAFTA text requires signatory countries to provide pharmaceutical corporations new monopoly powers to block generic competition. Among other dangerous terms, NAFTA 2.0 requires governments to guarantee 10 years of data exclusivity for biologic drugs. This would lock the United States into our bad policies that keep these medicines, including critical cancer treatments, outrageously expensive and export our failed system to Mexico and Canada.
Removing these harmful medicines provisions from the revised NAFTA is a top demand of civil society organizations and members of Congress.
NAFTA 2.0's Special Giveaways to Big Pharma
Download our latest resource highlighting NAFTA 2.0's special giveaways to Big Pharma.
Public Citizen's NAFTA 2.0 Text Analysis
The revised NAFTA deal that Donald Trump signed would lock in high U.S. medicine prices. Read our analysis.